U.S. Anatomic Pathology Market
Description
U.S. Anatomic Pathology Market Summary
The U.S. anatomic pathology market size was estimated at USD 9.71 billion in 2024 and is projected to reach USD 15.35 billion by 2030, growing at a CAGR of 7.1% from 2025 to 2030. This market is experiencing robust growth driven by technological innovation and growing clinical demands.
Integrating automation and digital solutions across all phases, such as pre-analytical, analytical, and post-analytical, is key to enhancing diagnostic accuracy, efficiency, and patient outcomes. The growing integration of advanced pathology equipment, such as gross imaging systems, digital microscopes, and automated staining platforms, is poised to enhance anatomic pathology practices.
Digital imaging technologies, in particular, deliver notable improvements in diagnostic specificity and accuracy over traditional methods. Consequently, the market for anatomic pathology is witnessing a surge in the adoption of these digital solutions, fueled by rising demand for diagnostic services that offer greater precision and reliability. In March 2023, PathAI, Inc. launched its AISight digital pathology platform and AIM-PD-L1 NSCLC RUO algorithm. Thirteen leading health systems, academic medical centers, and independent pathology organizations and reference laboratories participated in AISight Early Access Program.
The growth of personalized and precision medicine in the U.S. significantly fuels demand for anatomic pathology services. Accurate and detailed tissue analysis has become essential as more treatments become tailored to a patient’s individual genetic and molecular profile. Anatomic pathologists play a central role by performing specialized testing on biopsy and surgical specimens-including immunohistochemistry (IHC), in situ hybridization, and next-generation sequencing (NGS)-to detect key biomarkers such as HER2, EGFR, KRAS, and PD-L1. These results directly guide the selection of targeted therapies in breast, lung, and colorectal cancers.
U.S. Anatomic Pathology Market Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anatomic pathology market report based on product & services, application, and end use.
The U.S. anatomic pathology market size was estimated at USD 9.71 billion in 2024 and is projected to reach USD 15.35 billion by 2030, growing at a CAGR of 7.1% from 2025 to 2030. This market is experiencing robust growth driven by technological innovation and growing clinical demands.
Integrating automation and digital solutions across all phases, such as pre-analytical, analytical, and post-analytical, is key to enhancing diagnostic accuracy, efficiency, and patient outcomes. The growing integration of advanced pathology equipment, such as gross imaging systems, digital microscopes, and automated staining platforms, is poised to enhance anatomic pathology practices.
Digital imaging technologies, in particular, deliver notable improvements in diagnostic specificity and accuracy over traditional methods. Consequently, the market for anatomic pathology is witnessing a surge in the adoption of these digital solutions, fueled by rising demand for diagnostic services that offer greater precision and reliability. In March 2023, PathAI, Inc. launched its AISight digital pathology platform and AIM-PD-L1 NSCLC RUO algorithm. Thirteen leading health systems, academic medical centers, and independent pathology organizations and reference laboratories participated in AISight Early Access Program.
The growth of personalized and precision medicine in the U.S. significantly fuels demand for anatomic pathology services. Accurate and detailed tissue analysis has become essential as more treatments become tailored to a patient’s individual genetic and molecular profile. Anatomic pathologists play a central role by performing specialized testing on biopsy and surgical specimens-including immunohistochemistry (IHC), in situ hybridization, and next-generation sequencing (NGS)-to detect key biomarkers such as HER2, EGFR, KRAS, and PD-L1. These results directly guide the selection of targeted therapies in breast, lung, and colorectal cancers.
U.S. Anatomic Pathology Market Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. anatomic pathology market report based on product & services, application, and end use.
- Product & Services Outlook (Revenue, USD Billion, 2018 - 2030)
- Instruments
- Microtomes & Cryostat microtomes
- Tissue processors
- Automatic strainers
- Whole Slide Imaging (WSI) Scanners
- Other products
- Consumables
- Reagents & Antibodies
- Probes & Kits
- Others
- Services
- Application Outlook (Revenue, USD Billion, 2018 - 2030)
- Disease Diagnosis
- Drug Discovery and Development
- Others
- End Use Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospitals
- Research Laboratories
- Diagnostic Laboratories
- Others
Table of Contents
80 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product & Services
- 1.2.2. Application
- 1.2.3. End Use
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product & services outlook
- 2.2.2. Application outlook
- 2.2.3. End use outlook
- 2.3. Competitive Insights
- Chapter 3. U.S. Anatomic Pathology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Anatomic Pathology Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. U.S. Anatomic Pathology Market: Pipeline Analysis
- Chapter 4. U.S. Anatomic Pathology Market: Product & Services Estimates & Trend Analysis
- 4.1. Product & Services Segment Dashboard
- 4.2. U.S. Anatomic Pathology Market: Product & Services Movement Analysis
- 4.3. U.S. Anatomic Pathology Market Size & Trend Analysis, by Product & Services, 2018 to 2030 (USD Billion)
- 4.4. Instruments
- 4.4.1. Microtomes & Cryostat microtomes
- 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.4.2. Tissue processors
- 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.4.3. Automatic strainers
- 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.4.4. Whole Slide Imaging (WSI) Scanners
- 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.4.5. Other products
- 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.5. Consumables
- 4.5.1. Reagents & Antibodies
- 4.5.1.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.5.2. Probes & Kits
- 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.5.3. Others
- 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD billion)
- 4.6. Services
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 5. U.S. Anatomic Pathology Market: Application Estimates & Trend Analysis
- 5.1. Application Segment Dashboard
- 5.2. U.S. Anatomic Pathology Market: Application Movement Analysis
- 5.3. U.S. Anatomic Pathology Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Billion)
- 5.4. Disease Diagnosis
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.5. Drug Discovery and Development
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.6. Others
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 6. U.S. Anatomic Pathology Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. U.S. Anatomic Pathology Market: End Use Movement Analysis
- 6.3. U.S. Anatomic Pathology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
- 6.4. Hospitals
- 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.5. Research Laboratories
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.6. Diagnostic Laboratories
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.7. Others
- 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. Key company heat map analysis, 2024
- 7.4. Company Profiles
- 7.4.1. Danaher Corporation
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Quest Diagnostics Incorporated
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Labcorp
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. Agilent Technologies, Inc.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Cardinal Health
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. Sakura Finetek USA, Inc.
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. NeoGenomics Laboratories, Inc.
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. BioGenex
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Bio SB
- 7.4.9.1. Company overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
